ASX Health Stocks: US market brings home the bacon for HeraMED and Respiri
Health & Biotech
Health & Biotech
Link copied to
Pregnancy medtech specialist, HeraMed (ASX:HMD), was up over 20% this morning after revealing a supply deal with US-based e-Lōvu Health.
The expected revenue to HeraMED from the deal is approximately US$550k.
e-Lōvu Health is a clinically guided digital marketplace in the US that helps mothers access health and wellness care from preconception to postpartum.
The company uses a range of proprietary and patent-pending technologies, for which HeraMED’s HeraCARE platform operates as the backbone.
Under the terms of the deal, 1,000 remote pregnancy monitoring kits including HeraBEATs and Bluetooth-connected blood pressure cuffs with HeraCARE connectivity will be supplied.
These kits are destined for 1000 expectant mothers at several identified e-Lōvu Health partner healthcare providers in the US.
The first site is expected to launch before the end of 2022, with an estimated full deployment within 6-12 months from signing this agreement.
“This formal agreement with e-Lōvu Health is an incredibly important milestone for HeraMED, and is the result of a high level of cooperation, trust, in addition to shared values and mission,” said HeraMED CEO and co-founder, David Groberman.
“The deal clearly validates the advantages of our technology and business model, and officially launches our commercialisation into the United States market.”
Respiratory health tech company Respiri (ASX:RSH) was up 8% this morning after announcing that it has successfully run a systems integration program with the Michigan Children’s Hospital ready for the first patient intake.
Respiri and Access Telehealth have integrated Respiri’s patient apps and devices (wheezo), as well as the Respiri Health portal that manages respiratory health data.
Access Telehealth’s RPM (Remote Patient Monitoring) management platform, Remotli, has also been integrated for doctors to monitor patients and claim reimbursement for services.
For the wheezo platform, data captured will include breath recordings, wheeze rates and other factors which may trigger exacerbations of disease such as pollution, pollen and medication usage.
wheezo is meant to provide doctors with a clearer picture around a patient’s respiratory condition, making it easier for them to determine if it is deteriorating and to act accordingly.
Marjan Mikel, Respiri CEO, said:
“This is a further significant milestone for Respiri, as this integration with our partner’s Access Remotli system helps remove one of the barriers to customer adoption of wheezo, and simplifies the processing of RPM reimbursement, both of which should streamlines the onboarding of future customers.”